三生国健: 三生国健：关于核心技术人员变动的公告

Core Viewpoint - The announcement details the resignation of core technical personnel Huang Haomin from Sangfor Biopharma, emphasizing that his departure will not adversely affect the company's core technologies, intellectual property, or ongoing research and development efforts [1][2][4]. Summary by Sections Personnel Changes - Huang Haomin has submitted his resignation due to a job transfer and will no longer hold any position within the company. His responsibilities will be taken over by Gu Jinming and the research team [2][3]. - Huang Haomin held 10,230 shares in the company, acquired through the 2021 restricted stock incentive plan, and will comply with relevant regulations regarding share reduction [3]. Impact on Research and Development - The company has established a robust research management and intellectual property protection system, ensuring that the change in core personnel will not affect the integrity of its core technologies and patent ownership [2][4]. - Huang Haomin's research work has been properly handed over, and his departure will not impact the progress of existing research projects [4][7]. New Core Technical Personnel - Gu Jinming has been recognized as a new core technical personnel member, with a strong background in molecular biology and extensive experience in research and development [5][6]. - The company maintains a complete research team structure and has a sufficient backup of personnel to support ongoing and future core technology development [7]. Company Measures - The company emphasizes its commitment to research and development, having built a comprehensive research system and a professional talent team capable of continuous innovation [6][7]. - Future plans include increasing investment in research and development and enhancing the recruitment and training of technical personnel [7].